Definitive Contract 75N93025C00035
Award Date
9/24/25
Potential Completion Date
2/7/29
Potential Value
$3.3M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Locus Biosciences Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Morrisville, NC, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
16
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a definitive cost-sharing contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) to Locus Biosciences Inc., a clinical-stage biopharmaceutical company, for the clinical development of a CRISPR-Cas3 phage cocktail to treat recurrent urinary tract infections caused by Escherichia coli, including antimicrobial and multi-drug resistant strains. The contract has a ceiling value of $91,817,550.73 and a completion...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded a $15,505,000.31 definitive cost-no-fee contract to Entasis Therapeutics Inc., a subsidiary of Innoviva, Inc., to identify and develop a non-beta-lactam penicillin-binding protein (PBP) inhibitor with broad-spectrum activity against multidrug-resistant Gram-negative ESKAPE pathogens. This work directly responds to a NIAID solicitation for proposals addressing...
This $1,797,717.00 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the National Institutes of Health (NIH), to Intralytix Inc., a biotechnology company specializing in bacteriophage-based products. The contract is for the development of a "Universal, Scalable Artificial Intelligence-Based Platform for Manufacturing High Titer Biopharmaceuticals", which aligns with...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $716,374 delivery order contract to Lovelace Biomedical Research Institute. Under the terms of the firm fixed price contract, Lovelace Biomedical Research Institute will conduct a Good Laboratory Practice repeat dose toxicology study for BPL-24910 in support of the Comprehensive and Rapid Response for NIAID Research Programs major program code. Performance...
This is a task order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. Department of Health and Human Services, to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a not-for-profit contract research organization. The task order, titled "PRE-CLINICAL MODELS OF INFECTIOUS DISEASES TASK ORDER B07", is part of NIAID's Preclinical Models of Infectious Diseases contract vehicle, which provides...
This is a task order award under a federal contract with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The $2,910,502 cost-plus-fixed-fee contract was awarded to Leidos, Inc., a global technology and engineering company, to provide preclinical services for the development of biopharmaceutical products targeting infectious diseases. The contract has a completion date of September 19, 2021 and was awarded on...
This contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to the Southern Research Institute, a corporate entity tax-exempt non-profit organization. The contract is a Delivery Order under the In Vitro Assessments of Antimicrobial Activity (IVAAA) Indefinite Delivery/Indefinite Quantity (ID/IQ) contract vehicle. The $1,275,123.00 cost-plus-fixed-fee contract is for evaluating therapeutic product...
This is a $4,469,522.01 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Agile Sciences, Inc., a small disadvantaged business. The contract is for "Targeting Therapeutics Development to Relieve Bottlenecks: Optimizing Lead Therapeutic Compounds Against Infectious Pathogens" and has an ultimate completion date of October 15, 2018. The contract was awarded on June 30, 2015 and was not set aside.
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Emory University. The $3,458,502.19 cost-no-fee contract is for "TARGETING THERAPEUTICS DEVELOPMENT TO RELIEVE BOTTLENECKS: OPTIMIZONG LEAD THERAPEUTIC COMPOUNDS AGAINST INFECTIOUS PATHOGENS." It has a period of performance through October 31, 2018. The contract is not designated as a set-aside. The contract has several...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $31,725,938.61 cost-plus-fixed-fee contract to Revagenix Inc. to select a novel small molecule antibiotic for clinical development and advance it through IND filing and Phase 1 clinical studies. This contract was not set aside and has an ultimate completion date of August 31, 2026. The contract originated from a NIAID Broad Agency Announcement seeking proposals to develop medical countermeasures to mitigate and/or...